Additional funding of $20 million accelerates commercialization of Trailhead's iPSC-derived human cell and media products.

SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...

Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...

Century intends to use the net proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes.

Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...

Cells can be reprogrammed, edited and differentiated into a wide variety of iPSC-derived cell types and 3-dimensional human cell models. iPSCore ™ incorporates extensive characterization, ...

Additional funding of $20 million accelerates commercialization of Trailhead's iPSC-derived human cell and media products.